Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Income from Continuing Operations (2019 - 2025)

Historic Income from Continuing Operations for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to -$7.3 million.

  • Keros Therapeutics' Income from Continuing Operations rose 8625.27% to -$7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.4 million, marking a year-over-year increase of 13432.12%. This contributed to the annual value of -$187.4 million for FY2024, which is 2245.93% down from last year.
  • Keros Therapeutics' Income from Continuing Operations amounted to -$7.3 million in Q3 2025, which was up 8625.27% from -$30.7 million recorded in Q2 2025.
  • Over the past 5 years, Keros Therapeutics' Income from Continuing Operations peaked at $148.5 million during Q1 2025, and registered a low of -$53.0 million during Q3 2024.
  • Over the past 5 years, Keros Therapeutics' median Income from Continuing Operations value was -$29.7 million (recorded in 2022), while the average stood at -$21.6 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first plummeted by 32821.33% in 2022, then soared by 44432.2% in 2025.
  • Over the past 5 years, Keros Therapeutics' Income from Continuing Operations (Quarter) stood at -$6.9 million in 2021, then crashed by 328.21% to -$29.7 million in 2022, then plummeted by 56.32% to -$46.5 million in 2023, then rose by 0.92% to -$46.0 million in 2024, then surged by 84.18% to -$7.3 million in 2025.
  • Its Income from Continuing Operations was -$7.3 million in Q3 2025, compared to -$30.7 million in Q2 2025 and $148.5 million in Q1 2025.